Advertisement

Supportive Treatment

  • Michael Daskalakis
  • Hartmut Bertz
  • Veronique Thierry
  • Claudia I. Müller
  • Monika Engelhardt
  • Antonia Müller
  • Gudrun Zürcher
  • U. Brunnmüler
  • Karin Potthoff
  • Jürgen Heinz
  • Elke Reinert
  • Hartmut Henß
  • Dietmar P. Berger
  • Alexander Kiani
  • Albrecht Leo
  • Eugen Leo
  • C. Keck
  • Hans-Peter Zahradnik
  • Ulrich Wetterauer
  • R. Schindler
  • S. Stobrawa
  • A. Schmid
  • Ursula Blattmann
  • Björn-Hans Rüter
  • Katrin Heeskens
  • Tanja Gölz
  • B. Stein
  • Alexander Wünsch
  • Gerhard Adam
  • Christoph Zeller

Keywords

Clin Oncol Enteral Nutrition National Comprehensive Cancer Network National Comprehensive Cancer Network Fresh Freeze Plasma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    ESMO Guidelines Working Group. Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis. Ann Oncol 2007;18(suppl 2):ii83–5Google Scholar
  2. 2.
    Grunberg SM, Deuson RR, Mavros P et al. Incidence of chemotherapy-induced nausea and emesis after modern anti-emetics. Cancer 2004;100:2261–8PubMedGoogle Scholar
  3. 3.
    Hesketh PJ, Kris MG, Grünberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103–9PubMedGoogle Scholar
  4. 4.
    Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 2005;41:199–205PubMedGoogle Scholar
  5. 5.
    Kris MG, Heskett PJ, Somerfield MR et al. ASCO Guideline for antiemetics in oncology. J Clin Oncol 2006;24:2932–47PubMedGoogle Scholar
  6. 6.
    Oettle H, Riess H. Treatment of chemotherapy-induced nausea and vomiting. J Cancer Res Clin Oncol 2001;127:340–5PubMedGoogle Scholar
  7. 7.
    Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 2003;8:187–98PubMedGoogle Scholar
  8. 1.
    http://www.mascc.org Supportive Care in Cancer, MASCCGoogle Scholar
  9. 2.
    http://www.guideline.gov National Guideline ClearinghouseGoogle Scholar
  10. 3.
    http://www.nccn.org/professionals/
physician_gls/PDF/antiemesis.pdf NCCN Guidelines AntiemesisGoogle Scholar
  11. 4.
    http://www.nlm.nih.gov/medlineplus/
ency/article/003117.htm Medline Plus, Nausea / VomitingGoogle Scholar
  12. 1.
    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228–37PubMedGoogle Scholar
  13. 2.
    De Pauw BE. Strategies in the treatment of infections in neutropenic patients. Med Microbiol Lett 1996;5:305–9Google Scholar
  14. 3.
    Hughes WT, Armstrong D, Bodey GP et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–51PubMedGoogle Scholar
  15. 4.
    Kern WV, Cometta A, De Bock R et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999;341:312–8PubMedGoogle Scholar
  16. 5.
    Neuburger S, Maschmeyer G. Update on managment of infections in cancer and stem cell transplant patients. Ann Hematol 2006;85:345–56PubMedGoogle Scholar
  17. 6.
    Pizo PA. Fever in immunocompromised patients. N Engl J Med 1999;341:893–900Google Scholar
  18. 7.
    Smith TJ, Khatcheressian J, Lyman GH et al. 2006 Update of recommendations for the use of white blood cell growth factors. An evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–205PubMedGoogle Scholar
  19. 1.
    http://www.guideline.gov National Guideline ClearinghouseGoogle Scholar
  20. 2.
    http://www.mascc.org Supportive Care in Cancer, MASCCGoogle Scholar
  21. 3.
    http://www.neutropenia.ca/ Neutropenia Support AssociationGoogle Scholar
  22. 4.
    http://www.nccn.org/professionals/physician_gls/
PDF/myeloid_growth.pdf NCCN GuidelineGoogle Scholar
  23. 1.
    Aapro MS. Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433–53Google Scholar
  24. 2.
    Bokemeyer M, Aapro MS, Courdia A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258–70PubMedGoogle Scholar
  25. 3.
    Clark OAC, Lyman GH, Castro AA et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomised controlled trials. J Clin Oncol 2005;23: 4198–214PubMedGoogle Scholar
  26. 4.
    Crawford J et al. Myeloid growth factors in cancer treatment. NCCN, Clinical Practice Guidelines in Oncology - v.2.2005Google Scholar
  27. 5.
    ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the application. Ann Oncol 2007;18(suppl 2):ii89–91Google Scholar
  28. 6.
    ESMO Guidelines Working Group. Erythropoietins in cancer patients: ESMO recommendations for use. Ann Oncol 2007;18(suppl 2):ii86–8Google Scholar
  29. 7.
    Rizzo JD, Somerfield MR, Hagerty KL et al. Use of epoetin and darbepoetin in patients with cancer: 2007 ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol 2008;26:132–49PubMedGoogle Scholar
  30. 8.
    Smith TJ, Khatcheressian J, Lyman GH et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: an evidence-based clinical practice guideline. J Clin Oncol 2005;24:3187–205Google Scholar
  31. 9.
    Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancer. N Engl J Med 2004;351:2590–8PubMedGoogle Scholar
  32. 1.
    http://www.asco.org ASCO, Am Soc Clin OncolGoogle Scholar
  33. 2.
    http://www.mascc.org Supportive Care in CancerGoogle Scholar
  34. 3.
    http://www.hematology.org ASH, Am Soc Clin OncolGoogle Scholar
  35. 4.
    http://www.esmo.org ESMO, Eur Soc Med OncolGoogle Scholar
  36. 5.
    http://www.guideline.gov National Guideline ClearinghouseGoogle Scholar
  37. 6.
    http://wwwahrq.gov/clinic/epcix.htm Agency for Healthcare Research and QualityGoogle Scholar
  38. 1.
    Arends J, Bodoky G, Bozzetti F et. al. ESPEN guidelines on enteral nutrition: non-surgical oncology. Clin Nutr 2006;25:245–59PubMedGoogle Scholar
  39. 2.
    Davis MP, Dreicer R, Walsh D et al. Appetite and cancer associated anorexia. J Clin Oncol 2004;22:1510–7PubMedGoogle Scholar
  40. 3.
    Detsky A, Mc Laughlin J. Baker J et al. What is Subjective Global Assessment of Nutritional Status? JPEN 1987;11:8–13Google Scholar
  41. 4.
    Doyle C, Kushi LH, Byers T et al. Nutrition and physical activity during and after cancer treatment. CA Cancer J Clin 2006;56:323–53PubMedGoogle Scholar
  42. 5.
    Morrison G, Hark L. Medical Nutrition and Disease. Blackwell Science, 1999Google Scholar
  43. 6.
    Nitenberg G, Raynard B. Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Hematol Oncol 2000;34:137–68Google Scholar
  44. 7.
    Skipworth R, Fearon KCK. The scientific rationale for otimizing nutritional support in cancer. Eur J Gastroenterol Hepatol 2007;19:371–7PubMedGoogle Scholar
  45. 1.
    http://www.mascc.org Multinational Association of Supportive Care in CancerGoogle Scholar
  46. 2.
    http://www.nutritioncare.org Am Soc Parental and Enteral NutritionGoogle Scholar
  47. 3.
    http://www.nutrition.org American Society for Clinical NutritionGoogle Scholar
  48. 4.
    http://www.cancer.org/docroot/MBC/MBC_6.asp Am Cancer Society, NutritionGoogle Scholar
  49. 5.
    http://www.espen.org Eur Soc Clin Nutrition MetabolismGoogle Scholar
  50. 1.
    ASPEN: Board of directors. Specific guidelines for disease adults: Cancer JPEN 2002;26:82SA–83SAGoogle Scholar
  51. 2.
    ASPEN: Board of directors. Specific guidelines for disease adults: Cancer - hematopoietic cell transplantation. JPEN 2002;26:83SA–85SAGoogle Scholar
  52. 3.
    Bozetti F, Cavazzi C, Mariani L et al. Artificial nutrition in cancer patients: which route, what composition? World J Surg 1999;23:577–83Google Scholar
  53. 4.
    Wilson RL. Optimizing nutrition for patients with cancer. Clin J Oncol Nurs 2000;4:23–8PubMedGoogle Scholar
  54. 1.
    http://www.mascc.org/ Multinational Association of Supportive Care in CancerGoogle Scholar
  55. 2.
    http://cancernet.nci.nih.gov/ CancerNet, with Information on Parenteral NutritionGoogle Scholar
  56. 3.
    http://www.nutritioncare.org/ Am Soc Parenteral Enteral NutritionGoogle Scholar
  57. 4.
    http://www.nutrition.org/ American Society for Clinical NutritionGoogle Scholar
  58. 1.
    Goldberg GR, Morrison RS. Pain management in hospitalized cancer patients. J Clin Oncol 2007;25:
1792–801PubMedGoogle Scholar
  59. 2.
    Jost LM. Management of cancer pain. ESMO Clinical Recommendations. Ann Oncol 2007;18(suppl 2):ii92–4PubMedGoogle Scholar
  60. 3.
    Levy MH, Samuel TA. Management of cancer pain. Semin Oncol 2005;32:179–93PubMedGoogle Scholar
  61. 4.
    McNicol E, Strassels S, Goudas L et al. Nonsteroidal anti-inflammatory drugs, alone or in combination with opioids, for cancer pain: a systematic review. J Clin Oncol 2004;22:1975–92PubMedGoogle Scholar
  62. 5.
    McQuay H. Opioids in pain management. Lancet 1999;353:2229–32PubMedGoogle Scholar
  63. 6.
    Mercadante S. The use of anti-inflammatory drugs in cancer pain. Cancer Treat Rev 2001;27:51–61PubMedGoogle Scholar
  64. 7.
    Van den Beuken-Van Everdingen MHJ, De Rijke JM, Kessels AG et al. Prevalence of pain in patients with cancer. Ann Oncol 2007;18:1437–49PubMedGoogle Scholar
  65. 1.
    http:// www.dgss.org DGSS, German Assoc. for the Study of PainGoogle Scholar
  66. 2.
    http://www.painresearch.utah.edu/cancerpain Cancer Pain ResourceGoogle Scholar
  67. 3.
    http://www.ampainsoc.org APS, American Pain SocietyGoogle Scholar
  68. 4.
    http://www.painmed.org/ AAPM, American Academy of Pain MedicineGoogle Scholar
  69. 5.
    http://www.cancer-pain.org/ Cancer Pain OrganisationGoogle Scholar
  70. 6.
    http://www.who.org WHO Pain LadderGoogle Scholar
  71. 7.
    http://www.nccn.org Cancer Pain GuidelinesGoogle Scholar
  72. 1.
    Carrol KK, Kohli S, Mustian KM et al. Pharmacologic treatment of cancer- related fatique. Oncologist 2007;12(suppl 1):43–52Google Scholar
  73. 2.
    Escalante CP. Treatment of cancer-related fatigue: an update. Support Care Cancer 2003;11:79–83PubMedGoogle Scholar
  74. 3.
    Glaus A. Fatigue in Patients with Cancer. Analysis and Assessment. Springer, Berlin Heidelberg New York, 1998Google Scholar
  75. 4.
    Iop A, Manfredi AM, Bonura S. Fatigue in cancer patients receiving chemotherapy. Ann Oncol 2004;15:712–20PubMedGoogle Scholar
  76. 5.
    Morrow GR, Shelke AR, Roscoe JA et al. Management of cancer-related fatigue. Cancer Invest 2005;22:229–39Google Scholar
  77. 6.
    Stasi R, Abriani L, Beccaglia P et al. Cancer-related fatigue. Cancer 2003;98:1786–801PubMedGoogle Scholar
  78. 7.
    Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 2004;91:822–8PubMedGoogle Scholar
  79. 1.
    http://www.nci.nih.gov/cancerinfo/pdq/supportivecare/ NCI PDQ, FatigueGoogle Scholar
  80. 2.
    http://www.nccn.org/professionals/physican_gls/PDF/fatique.pdf NCCN Fatigue GuidelinesGoogle Scholar
  81. 3.
    http://www.cancer.org/docroot/MIT/MIT_2_2x_Fatigue.asp ACS, FatigueGoogle Scholar
  82. 1.
    Berenson JR, Hillner BE, Kyle RA et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719–36PubMedGoogle Scholar
  83. 2.
    Clézardin P, Ebetino FH, Fournier PGJ. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971–4PubMedGoogle Scholar
  84. 3.
    Coleman RE. Bisphosphonates in breast cancer. Ann Oncol 2005;16:687–95PubMedGoogle Scholar
  85. 4.
    Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–57PubMedGoogle Scholar
  86. 5.
    Lüftner D, Henschke P, Possinger K. Clinical value of bisphosphonates in cancer therapy. Anticancer Res 2007;27:1759–68PubMedGoogle Scholar
  87. 6.
    Santini D, Vespasiani Gentilucci U, Vincenzi B et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003;14:1468–76PubMedGoogle Scholar
  88. 7.
    Wu S, Dahut WL, Gulley, JL. The use of bisphosphonates in cancer patients. Acta Oncol 2007;46:581–91PubMedGoogle Scholar
  89. 1.
    http://www.asco.org/ ASCO GuidelinesGoogle Scholar
  90. 2.
    http://www.multiplemyeloma.org/ Multiple Myeloma ResearchGoogle Scholar
  91. 3.
    http://www.ama-assn.org/ American Medical AssociationGoogle Scholar
  92. 4.
    http://courses.washington.edu/bonephys/opbis.html BisphosphonatesGoogle Scholar
  93. 5.
    http://www.cancerbackup.org.uk/
Treatments/Supportivetherapies/Bisphosphonates Cancer BackupGoogle Scholar
  94. 6.
    http://www.cochrane.org/reviews/en/index_list_b.html Cochrane LibraryGoogle Scholar
  95. 1.
    Convey AM. Management of malignant pleural effusions and ascites. J Support Oncol 2005;3:169–76Google Scholar
  96. 2.
    Nelson KA, Walsh D, Abdullah O et al. Common complications of advanced cancer. Semin Oncol 2000;27:34–44PubMedGoogle Scholar
  97. 1.
    http://www.uic.edu/classes/pmpr/pmpr652/Final/
bressler/maligeffu.html University of Illinois EducationGoogle Scholar
  98. 2.
    http://www.cancer.gov/cancertopics/pdq/
supportivecare/cardiopulmonary/HealthProfessional/page3 NCIGoogle Scholar
  99. 1.
    Alexandrakis MG, Passam FH, Kyriakou DS et al. Pleural effusions in hematologic malignancies. Chest 2004;125:1546–55PubMedGoogle Scholar
  100. 2.
    Antony VB, Loddenkemper R, Astoul P et al. Management of malignant pleural effusions. Eur Respir J 2001;18:402–19PubMedGoogle Scholar
  101. 3.
    Antunes G, Neville E, Duffy J et al. BTS guidelines for the management of malignant pleural effusions. Thorax 2003;58:29–38Google Scholar
  102. 4.
    Light RW. Pleural effusion. N Engl J Med 2002;346:1971–7PubMedGoogle Scholar
  103. 5.
    Pollak JS. Malignant pleural effusions: treatment with tunneled long-term drainage catheters. Curr Opin Pulm Med 2002;8:302–7PubMedGoogle Scholar
  104. 6.
    Rahman NM, Chapman SJ, Davies RJ. Pleural effusion: a structured approach to care. Br Med Bull 2005;72:31–47PubMedGoogle Scholar
  105. 7.
    Tarn AC, Lapworth R. Biochemical analysis of pleural analysis of pleural fluid: what should we measure? Ann Clin Biochem 2001;38:311–22PubMedGoogle Scholar
  106. 8.
    Tassi GF, Cardillo G, Marchetti GP et al. Diagnostic and therapeutical management of malignant pleural effusion. Ann Oncol 2006;17(suppl 2):ii11–2PubMedGoogle Scholar
  107. 1.
    http://www.merck.com/mmpe/sec05/ch060/ch060d.html Merck ManualGoogle Scholar
  108. 2.
    http://www.meds.com/pdq/effusion_pro.html Medicine OnlineGoogle Scholar
  109. 3.
    http://www.emedicine.com/EMERG/topic462.htm EmedicineGoogle Scholar
  110. 4.
    http://www.emedicine.com/med/topic1843.htm Pleural Effusion, EmedicineGoogle Scholar
  111. 5.
    http://www.nlm.nih.gov/medlineplus/ency/article/000086.htm Medline PlusGoogle Scholar
  112. 1.
    Chen EP, Miller JI. Modern approaches and use of surgical treatment for pericardial disease. Curr Cardiol Rep 2002;41:4–6Google Scholar
  113. 2.
    Keefe DL. Cardiovascular emergencies in the cancer patient. Semin Oncol 2000;27:244–55PubMedGoogle Scholar
  114. 3.
    Maher EA. Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg 1996;112:637–43PubMedGoogle Scholar
  115. 4.
    Maisch B, Sererovic PM, Ristic AD et al. Guidelines on the diagnosis and management of effusions. Eur Soc Cardiol, 2004Google Scholar
  116. 5.
    Martinoni A, Cipolla CM, Civelli M et al. Intrapericardial treatment of neoplastic pericardial effusions. Herz 2000;25:787–93PubMedGoogle Scholar
  117. 6.
    Retter AS. Pericardial disease in the oncology patient. Heart Dis 2002;4:387–91PubMedGoogle Scholar
  118. 7.
    Shepherd FA. Malignant pericardial effusion. Curr Opin Oncol 1997;9:170–4PubMedGoogle Scholar
  119. 1.
    http://www.emedicine.com/med/topic1786.htm Pericardial Effusion, e-medicineGoogle Scholar
  120. 2.
    http://www.nlm.nih.gov/medlineplus/ency/article/000194.htm Medline PlusGoogle Scholar
  121. 3.
    http://www.nci.nih.gov/cancertopics/pdq/supportivecare/
cardiopulmonary/HealthProfessional NCI PDQGoogle Scholar
  122. 1.
    Becker G, Galandi D, Blum HE. Malignant ascites: Systematic review and guideline for treatment. Eur J Cancer 2006;42:589–97PubMedGoogle Scholar
  123. 2.
    Jeffery J, Murphy MJ. Ascitic fluid analysis: the role of biochemistry and haematology. Hosp Med 2001;62:282–6PubMedGoogle Scholar
  124. 3.
    Markmann M. Intraperitoneal chemotherapy. Semin Oncol 1991;18:248–54Google Scholar
  125. 4.
    McHutchinson JG. Differential diagnosis of ascites. Semin Liver Dis 1997;17:191–202Google Scholar
  126. 5.
    Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg 1996;83:6–14PubMedGoogle Scholar
  127. 6.
    Runyon BA. Care of patients with ascites. N Engl J Med 1994;330:337–42PubMedGoogle Scholar
  128. 7.
    Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol 2003;15:59–72Google Scholar
  129. 1.
    http://www.cancerweb.ncl.ac.uk/cancernet/103862.html Malignant Ascites, CancernetGoogle Scholar
  130. 2.
    http://www.surgicaloncology.com/psmreslt.htm Surgical OncologyGoogle Scholar
  131. 3.
    http://www.emedicine.com/med/topic173.htm EmedicineGoogle Scholar
  132. 1.
    American Association of Blood Banks, Association Bulletins #97/2 and #02-4Google Scholar
  133. 2.
    BCSH (British Committee for Standards in Hematology). Guidelines for the use of platelet transfusions. Br J Haematol 2003;122:10–23Google Scholar
  134. 3.
    Goodnough LT, Brecher ME, Kantner MH et al. Transfusion medicine. N Engl J Med 1999;340:438–47, 525–33Google Scholar
  135. 4.
    Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet 2007;370:415–26PubMedGoogle Scholar
  136. 5.
    Stroncek DF, Rebulla P. Platelet transfusions. Lancet 2007;370:427–38PubMedGoogle Scholar
  137. 6.
    Triulzi DJ. Blood Transfusion Therapy: A Physician’s Handbook, 7th edn. AABB Bookstore, 2002Google Scholar
  138. 7.
    Wandt H, Ehninger G, Gallmeier WM. New strategies for prophylactic platelet transfusion in patients with hematologic diseases. The Oncologist 2001;6:446–50PubMedGoogle Scholar
  139. 1.
    http://www.aabb.org/ American Association of Blood BanksGoogle Scholar
  140. 2.
    http://www.bbts.org.uk/ British Blood Transfusion SocietyGoogle Scholar
  141. 3.
    http://www.ohsu.edu/pathology/transman/index.html Transfusion ManualGoogle Scholar
  142. 4.
    http://www.who.int/bloodsafety/en/ WHO Site on Blood SafetyGoogle Scholar
  143. 1.
    Farrugia A, Poulis P. Intravenous immunoglobulin: regulatory perspectives on use and supply. Transfus Med 2001;11:63–74PubMedGoogle Scholar
  144. 2.
    Hellstern P, Halbmayer WM, Köhler M et al. Prothrombin complex concentrates: indications, contraindications and risks. Thromb Res 1999;95:S3–6PubMedGoogle Scholar
  145. 3.
    Key NS. Coagulation factor concentrates. Lancet 2007;370:439–48PubMedGoogle Scholar
  146. 4.
    Staudinger T, Frass M, Rintelen C et al. Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med 1999;25:1105–10PubMedGoogle Scholar
  147. 1.
    http://www.med.unc.edu/isth International Society on Thrombosis and HaemostasisGoogle Scholar
  148. 1.
    Anger JT, Gilbert BR, Goldstein M. Cryopreservation of sperm: indications, methods and results. J Urol 2003;170:1079–84PubMedGoogle Scholar
  149. 2.
    Crockin SL. Legal issues related to parenthood after cancer. J Natl Cancer Inst Monogr 2005;34:111–13PubMedGoogle Scholar
  150. 3.
    Lee SJ, Schover LR, Partridge AH et al. ASCO recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917–31PubMedGoogle Scholar
  151. 4.
    Orwig KE, Schlatt S. Cryopreservation and transplantation of spermatogonia and testicular tissue for the preservation of male fertility. J Natl Cancer Inst Monogr 2005;34:51–6PubMedGoogle Scholar
  152. 5.
    Postovsky S, Lightman A, Aminpour D et al. Sperm cryopreservation in adolescents with newly diagnosed cancer. Med Pediatr Oncol 2003;40:355–9PubMedGoogle Scholar
  153. 6.
    Puschek E, Philip PA, Jeyendran RS. Male fertility preservation and cancer treatment. Cancer Treat Rev 2004;30:173–80Google Scholar
  154. 7.
    Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered ? Lancet Oncol 2005;6:209–18PubMedGoogle Scholar
  155. 1.
    http://www.givf.com/ Genetics and IVF InstituteGoogle Scholar
  156. 2.
    http://www.nci.nih.gov/cancertopics/pdq/supportivecare/
sexuality/HealthProfessional/page6 NCI PDQGoogle Scholar
  157. 3.
    Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy. Curr Opin Obstet Gynecol 2005;17:21–6PubMedGoogle Scholar
  158. 4.
    Lee SJ, Schover LR, Partridge AH et al. ASCO recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917–31PubMedGoogle Scholar
  159. 5.
    Patrizio P, Butts S, Caplan A. Ovarian tissue preservation and future fertility: emerging technologies and ethical considerations. J Natl Cancer Inst Monogr 2005;34:107–10PubMedGoogle Scholar
  160. 6.
    Practice Committee of the American Society for Reproductive Medicine. Ovarian tissue and oocyte cryopreservation. Fertil Steril 2004;82:933–8Google Scholar
  161. 7.
    Roberts JE, Oktay K. Fertility preservation: a comprehensive approach to the young woman with cancer. J Natl Cancer Inst Monogr 2005;34:57–9PubMedGoogle Scholar
  162. 1.
    http://www.givf.com/ Genetics and IVF InstituteGoogle Scholar
  163. 2.
    http://www.nci.nih.gov/cancertopics/pdq/supportivecare/
sexuality/HealthProfessional/page6 NCI PDQGoogle Scholar
  164. 1.
    Basson R, Schultz WW. Sexual sequelae of general medical disorders. Lancet 2007;369:409–24PubMedGoogle Scholar
  165. 2.
    Derogatis LR, Kourlesis SM. An approach to evaluation of sexual problems in the cancer patient. CA Cancer J Clin 1981;31:46–50PubMedGoogle Scholar
  166. 3.
    Hollenbeck BK, Dunn RL, Wei JT et al. Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage breast cancer. Curr Urol Rep 2994;5:212–19Google Scholar
  167. 4.
    Kornblith AB, Ligibel J. Psychosocial and sexual functioning of survivors of breast cancer. Semin Oncol 2003;30:799–913PubMedGoogle Scholar
  168. 5.
    Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802–13PubMedGoogle Scholar
  169. 6.
    Wilmoth MC, Botchway P. Psychosexual implications of breast and gynecologic cancer. Cancer Invest 1999;17:631–6PubMedGoogle Scholar
  170. 1.
    http://www.meb.uni-bonn.de/cancer.gov/CDR0000062859.html CancernetGoogle Scholar
  171. 2.
    http://cancernet.nci.nih.gov/cancertopics/pdq/supportivecare CancernetGoogle Scholar
  172. 3.
    http://www.cancerbackup.org.uk/info/sexuality.htm CancerBACKUPGoogle Scholar
  173. 1.
    Dimeo F, Stieglitz RD, Novelli-Fischer U et al. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer 1999;85:2273–7PubMedGoogle Scholar
  174. 2.
    Knols R, Aaronson NK, Uebelhart D et al. Physical exercise in cancer patients during and after medical treatment. J Clin Oncol 2005;23:3830–42PubMedGoogle Scholar
  175. 3.
    McTiernan A. Physical activity after cancer: physiologic outcomes. Cancer Invest 2004;22:68–81PubMedGoogle Scholar
  176. 4.
    Meyerhardt JA, Heseltine D, Niedzwiecki D et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer. J Clin Oncol 2006;24:3535–41PubMedGoogle Scholar
  177. 5.
    Stevinson C, Lawlor DA, Fox KR. Exercise interventions for cancer patients. Cancer Causes Control 2004;15:1035–56PubMedGoogle Scholar
  178. 1.
    http://www.apta.org Am Physical Therapy AssocGoogle Scholar
  179. 2.
    Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for prevention and treatment of mucositis. Cancer 2007;109:820–31PubMedGoogle Scholar
  180. 3.
    Stevenson J, Abernethy P A, Miller C, Currow DC. Managing comorbidities in patients at the end of life. BMJ 2004;329;909–12PubMedGoogle Scholar
  181. 1.
    http://www.ons.org Oncology Nursing SocietyGoogle Scholar
  182. 2.
    http://www.harcourt-international.com/journals/ejon/ European Journal of Oncology NursingGoogle Scholar
  183. 1.
    Faller H, Bülzebruck H. Coping and survival in lung cancer: a 10-year follow-up- Am J Psychiatry 2002;159:2105–7PubMedGoogle Scholar
  184. 2.
    Fawzy FI, Fawzy NW. A structured psychoeducational intervention for cancer patients. Gen Hosp Psychiatry 1994;16:149–92PubMedGoogle Scholar
  185. 3.
    Fritzsche K, Stein B, Herzog T et al. Psychosocial care of oncological in-patients. An empirical study of psychiatric and psychosomatic consultation services. Onkologie 1998;21:150–5Google Scholar
  186. 4.
    Greer S, Moorey S, Baruch JD, Watson M, Robertson BM, Mason A, Rowden L, Law MG, Bliss JM. Adjuvant psychological therapy for patients with cancer: a prospective randomised trial. Br Med J 1992;304:675–80Google Scholar
  187. 5.
    Jenkins V, Fallowfield L, Saul J. Information need of patients with cancer: results from a large study in UK cancer centres. Br J Cancer 2001;84:48–51PubMedGoogle Scholar
  188. 6.
    Kendall WS. Suicide and cancer: a gender-comparative study. Ann Oncol 2007;18:381–7Google Scholar
  189. 1.
    http://www.dapo-ev.de German Association of Psychosocial-oncologyGoogle Scholar
  190. 2.
    http://www.ipos-society.org/ International Psychooncology SocietyGoogle Scholar
  191. 3.
    www.psycho-oncology.net International Directory of Psycho-oncology ProgramsGoogle Scholar
  192. 1.
    Cheville AL. Cancer rehabilitation. Semin Oncol 2005;32:219–24PubMedGoogle Scholar
  193. 2.
    World Health Organization (WHO) 2001. International Classification of Functioning, Disability and Health (ICF). WHO Publication, GenevaGoogle Scholar
  194. 1.
    http://www.emedicine.com/pmr/topic226.htm emedicineGoogle Scholar
  195. 2.
    http://www.northeastrehab.com/Programs/oncology.htm Northeast Rehab Health NetworkGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Michael Daskalakis
    • 1
  • Hartmut Bertz
    • 1
  • Veronique Thierry
    • 1
  • Claudia I. Müller
    • 1
  • Monika Engelhardt
    • 2
  • Antonia Müller
    • 1
  • Gudrun Zürcher
    • 1
  • U. Brunnmüler
  • Karin Potthoff
    • 3
  • Jürgen Heinz
    • 2
  • Elke Reinert
    • 4
  • Hartmut Henß
    • 4
  • Dietmar P. Berger
    • 2
  • Alexander Kiani
    • 5
  • Albrecht Leo
    • 6
  • Eugen Leo
    • 7
  • C. Keck
  • Hans-Peter Zahradnik
    • 1
  • Ulrich Wetterauer
    • 8
  • R. Schindler
  • S. Stobrawa
  • A. Schmid
  • Ursula Blattmann
    • 9
  • Björn-Hans Rüter
    • 1
  • Katrin Heeskens
    • 10
  • Tanja Gölz
    • 1
  • B. Stein
  • Alexander Wünsch
    • 1
  • Gerhard Adam
    • 11
  • Christoph Zeller
    • 11
  1. 1.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  2. 2.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  3. 3.Department of Translational OncologyNational Center for Tumor Diseases Heidelberg(NCT)HeidelbergGermany
  4. 4.Comprehensive Cancer Center FreiburgTumorzentrum Ludwig HeilmeyerFreiburgGermany
  5. 5.Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav CarusTechnical University DresdenDresdenGermany
  6. 6.Institute of Immunology, Serology and Transfusion MedicineRuprecht-Karls University HeidelbergHeidelbergGermany
  7. 7.Johnson & JohnsonBeerseBelgium
  8. 8.Department of UrologyUniversity Medical CenterFreiburgGermany
  9. 9.Central Physiotherapy, Department of Internal MedicineUniversity Medical CenterFreiburgGermany
  10. 10.Department of Gastroenterology, Hepatology, Endocrinology and Infectious DiseasesUniversity Medical CenterFreiburgGermany
  11. 11.Fachklinik f. Innere Medizin, Hematologie/OnkologieAsklepios Klinik TribergTribergGermany

Personalised recommendations